Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. North America is one of the most prominent markets for conjugate vaccines. The conjugate vaccine market in North America is expected to expand at a CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume, it is anticipated to reach 286.63 Million units by 2023 expanding at a CAGR of 3%.
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. Latin America is a market with a significant growth rate for conjugate vaccines. The conjugate vaccine market in Latin America is expected to grow at a CAGR of 20.4% leading to revenue of USD 5.43 Bn by 2023. By volume, it is anticipated to reach 839.21 Million units by 2023, expanding at a CAGR of 20.19%.
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. Europe is a market with stable growth for conjugate vaccines. The conjugate vaccine market in Europe is expected to expand at a CAGR of 3.6% leading to a revenue of USD 8.94 Bn by 2023. By volume, it is anticipated to reach 504.46 Million units by 2023, expanding at a CAGR of 3.7%.
Conjugate Vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. EU5 is one of the most prominent markets for conjugate vaccines.
The U.K. was the first country to introduce MenB-4C into their National Infant Immunization Program (2015). In all EU/EEA countries, Hib vaccination has been part of the immunization programs, since 2010, and high coverage has been sustained ... Read more